Regarding active clinical symptoms, manifestations of SLE (81.8% vs. 42.1%) and SSc (100.0% vs. 73.7%) were more frequently observed in anti-SMN antibody-positive patients than in antibody-negative patients. Here, SMN1 is linked to systemic sclerosis.